吡柔比星与表柔比星在乳腺癌新辅助化疗中的成本-效果分析

目的:比较吡柔比星与表柔比星在乳腺癌新辅助化疗中的成本-效果。方法:将188例乳腺癌新辅助化疗患者按治疗方案的不同分为CTF组(91例)与CEF组(97例)。CTF组术前经吡柔比星+环磷酰胺+氟尿嘧啶辅助化疗;CEF组术前经表柔比星+环磷酰胺+氟尿嘧啶辅助化疗,2组均进行4个周期。治疗后运用药物经济学原理进行成本-效果分析。结果:2组治疗总有效率为86.8%和90.7%,差异无统计学意义(P>0.05);2组均出现不同程度的不良反应,但差异无显著性(P>0.05)。CTF与CEF组的成本-效果比分别为198.59和248.73,2组比较差异有统计学意义(P<0.05)。结论:吡柔比星新辅助化疗方案治疗乳腺癌与表柔比星方案疗效相当,但更为经济。

Cost-effectiveness Analysis of Pirarubicin vs. Epirubicin for Neoadjuvant Chemotherapy of Breast Cancer

OBJECTIVE： To evaluate the Pharmacoeconomics effect of Pirarubicin and Epirubicin for neoadjuvant chemothera- py of breast cancer. METHODS： 188 patients with breast cancer were assigned to 2 groups treated by CTF （Pirarubicin, Cyclophos- phamide and fluorouracil） and CEF （Epirubicin, Cyclophosphamide and fluorouracil） chemotherapy respectively. 4 periods were taken by both groups, and the cost-effectiveness was taken to compare. RESULTS：The effective rates were 86.8% for CTF Group and 90.7% for CEF group （P〉0.05）. The cost-effectiveness ratios were 198.59 and 248.73, respectively. Both of 2 groups had ADRs in different degree, but there was no difference between both （P〉0.05）. CONCLUSION： Compared with CEF chemothera- py, CTF chemotherapy has pharmacoeconomical advantages for neoadjuvant chemotherapy of breast cancer.